Rituximab for rheumatoid arthritis
Palylyk-Colwell E, McGahan L
Record ID 32006000952
English
Authors' objectives:
The aim of this report is to assess the available information on the use of rituximab for rheumatoid arthritis.
Authors' recommendations:
Rituximab (RTX), a monoclonal antibody, selectively targets CD20+ B-cells that are implicated in the pathogenesis of rheumatoid arthritis (RA).
The use of RTX with methotrexate (MTX) results in statistically significant clinical improvements among RA patients who have an inadequate response to standard therapies, when compared to the use of MTX alone.
The optimal dose, duration of treatment or retreatment, long-term efficacy and safety, and placement of RTX in RA treatment algorithms need to be further investigated.
Health Canada has approved the combination of RTX with MTX for use in adult patients with moderate to severe active RA, who have had an inadequate response or intolerance to >1 tumour necrosis factor (TNF) inhibitor therapies.
Authors' methods:
Overview
Details
Project Status:
Completed
URL for project:
http://www.cadth.ca/media/pdf/E0001_rituximab_cetap_e.pdf
Year Published:
2006
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Antibodies, Monoclonal
- Antirheumatic Agents
- Arthritis, Rheumatoid
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.